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1. Introduction 
When Schubert introduced [l] the concept of 
‘effective’ or ‘conditional’ stability constants he did 
so in order to represent the ability of ligands to bind 
metal ions in vivo. He recognised that the extent of 
this binding would be determined not only by the 
metal-ligand formation constant but also by other 
parameters, in particular the ligand’s protonation 
constants and the equilibrium constants of any other 
competitive metal-ion-ligand interactions in the 
physiological medium. This approach was successful 
in showing how the calcium complex of polyamino- 
carboxylic acids could modify their therapeutic 
capacity for bifiding-other metal ions [ 1 ] . 
Nevertheless, many research workers still attempt 
to correlate the biological response to chelating 
agents simply with the 1 : 1 complex formation 
constant. One reason is that the calculation of effec- 
tive stability constants is not straightforward, 
particularly when many side-reactions need to be 
considered. There are also other difficulties with 
Schubert’s approach; for example, the relative effects 
of concentration are obscure. A more fundamental 
issue is that in vivo the ligand may form more than 
one complex species in significant concentrations. In 
addition to the complexes which might be protonated 
to differing extents, there may be ternary complexes 
formed in conjunction with naturally occurring 
ligands. 
Our recent publications of computer models 
involving many thousand complexing reactions 
permit a more basic and comprehensive study of 
metal-ion equilibria in biofluids [2]. Because 
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important metal-protein interactions are still too 
poorly characterised to be included satisfactorily in 
such simulations, methods of establishing and 
depicting results in a manner independent of these 
protein equilibria must be found. The large difference 
in the concentrations of proteins and of low molecular 
weight ligands compared with the concentrations of 
most metals in blood plasma makes this possible. 
Thus, it has been shown that although the absolute 
concentrations of metal complexes are controlled by 
the extent of protein binding, the percentage distribu- 
tion of transition metal ions amongst low molecular 
weight ligands is not [2]. 
2. Methods 
2.1. Plasma Mobilizing Index (PM) 
We now report an extension of this approach to 
include a number of therapeuticals in current use 
which promote the excretion of Cu, Fe, Mn, Pb, or 
Zn. The relative ability of each agent to compete for 
these metals in the biofluids has been obtained by 
calculating a ‘Plasma Mobilizing Index’ (PMI) from 
the computer simulation results. For each metal ion, 
we define 
(total concentration of low molecular weight 
metal complex species in the presence of the drug) 
PM1 = 
(total concentration of low molecular weight 
metal complex species in normal plasma) 
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Considering the blood plasma compartment as a 
closed system, this index is a convenient measure of 
the ability of the chelating agent, at a given concen- 
tration, to mobilize metal-ions from the labile protein- 
bound fraction. This arises because the free metal-ion 
concentration is buffered by the metal-protein 
complex until the agent has bound an appreciable 
fraction of this exchangeable metal in plasma. The 
effect of errors associated with protein binding, as 
previously discussed, is eliminated because the 
uncertain absolute value of the free metal-ion concen- 
tration appears as a factor in all terms in both the 
numerator and the denominator of the PM1 expression. 
3. Results and discussion 
Our studies reveal the considerable importance and 
general applicability of two factors in determining the 
physiological response towards a chelating agent. 
(1) The agent must be capable of competing effectively 
for exchangeable protein-bound metal-ions in 
blood plasma. 
(2) The lipophilicity of the predominant complexes 
in plasma as determined by their charge, controls 
the metal-ion distribution between body 
compartments. 
Whilst other contributions to the pharmacokinetics 
of the complexes can obviously be expected, the 
results of computer models, interpreted in accordance 
with the above two concepts, rationalise, on a chemical 
basis, a substantial number of observations concerning 
chelation therapy, as will now be illustrated. 
The PMI-curves calculated for ethylenediamine- 
tetraacetic acid (EDTA), diethylenetriaminepenta- 
acetic acid (DTPA), cyclohexylenedinitrilotetraacetic 
acid (CDTA), desferrioxamine (DFO), penicillamine 
(Pen), 2,3-dimercaptopropanol (BAL) and triethyl- 
enetetramine (Trien) are shown in tig.1. Their order 
correlates strikingly well with the ability of these 
agents to promote trace-metal excretion. Although 
direct comparisons in the literature are sparse, the 
relative physiological efficacies appear to be as follows. 
For Cu, Trien > DTPA > EDTA [3,4]. For Fe, DFO, 
CDTA > DTPA > EDTA > no effect [ 51. For Mn, 
CDTA = DTPA > EDTA > Pen = DFO = no effect 
[6,7]. For Pb, DTPA > EDTA > CDTA > Pen % 
BAL > DFO = no effect [8,9]. For Zn, DTPA, 
CDTA > EDTA > Pen > DFO = no effect [ 10,111. 
The good correlation between calculated and 
observed parameters is most significant when one 
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Fig.1. PM1 Curves with all seven chelating agents have been 
calculated for each metal-ion. Where these are omitted from 
fig.1 the agent is unable to compete in vivo for the metal 
in question. Note that the exceptionally high PMI-values 
computed for DFO are in practice offset by the rapid meta- 
bolic degradation of this agent leading to relatively low total 
concentrations in the plasma. 
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considers the relative differences in biological response 
elicited by the chelating agents rather than their 
exact positions in the comparative series just given. 
In this regard the PMI-values, unlike the formation 
constants (see table 1) accurately portray the phys- 
iological properties. For example, if the excretion of 
Pb and Zn caused by DTPA, EDTA and Pen is 
considered, both the similarity of these ligands in 
their effect on Pb [8] and the systematic difference 
they display towards Zn [ 10,ll J are reflected in fig. 1. 
The one noticeable anomaly in this study is the 
cupresis induced by penicillamine. The figure 
indicates that Pendisulphide is unable to compete 
successfully for Cu(I1) in plasma. Hence, we have 
recently challenged the view that Pen exerts its very 
considerable effect by acting as a chelating agent 
[ 121. Instead, it was proposed that copper may be 
liberated from (inert) metalloproteins by reduction 
to Cu(1). This hypothesis is in accord with several 
experimental studies [ 11,131. 
Table 1 
Important species formed by chelating agents in blood plasma as found by computer simulation 
Chelating agent 
administereda 
Species formed Formation constantb 
(log values) 
Percentage 
total ligandC 
Percentage total metal in 
low mol. wt fractionC 
DTPA 
CDTA 
DFO 
Pen 
EDTA Ca.EDTA*- 10.4 73 - 
Zn.EDTA’- 16.0 26 100 
Cu.EDTA*- 18.5 -0 84 
Fe.EDTA- 24.8 -0 71 
Fe.EDTA.OH*- 30.5 -0 23 
Pb.EDTA’- 17.1 -0 100 
Mn.EDTA’- 13.6 -0 100 
Zn.DTPA’- 17.8 
Ca.DTPA3- 10.6 
Cu.DTPA3- 21.0 
Fe.DTPA’- 27.8 
Pb.DTPA3- 18.6 
Mn.DTPA3- 15.3 
91 
7 
-0 
-0 
-0 
-0 
98 
_ 
99 
99 
100 
100 
Zn.CDTA’- 18.6 
Ca.CDTA’- 12.0 
Cu.CDTA’- 21.7 
Fe.CDTA.OH*‘ 36Sd 
Fe.CDTA- 28.0 
Pb.CDTA’- 19.1 
Mn.CDTA2- 16.4 
II 
22 
-0 
-0 
-0 
-0 
-0 
100 
- 
98 
99 
100 
100 
Fe.DFO’ 29.8 
Fe.DFO.OH 34.0 
H,.DFO+ 26.8 
Zn.DFO 11.0 
98 99 
-0 
- 
8 
H,.Pen 18.1 40 
Zn.Penz- 18.7 20 
H.Pen- 10.3 16 
Zn.H.Pen; 25.0 2 
Cu.H.OxPen.His 25.3 -0 
Cu.OxPen.His- 17.6 -0 
Pb.Pen 12.5 -0 
Pb.H.Pen; 26.4 -0 
Pb.Pen.Cit’- 16.2 -0 
Mn.Pen 5.0 -0 
- 
89 
7 
54 
21 
56 
35 
8 
1 
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Table 1 (continued) 
Chelating agent 
administereda 
Species formed Formation constantb 
(log values) 
Percentage 
total ligandC 
Percentage total metal in 
low mol. wt fractionC 
BAL Zn.BAL’- 
H,BAL 
Zn.BAL 
Pb.BAL 
Pb.BAL;- 
22.0 38 84 
19.2 16 - 
13.0 6 14 
14.0 -0 97 
20.5d -0 2 
H, .Trien’+ 
Hs .Trien* 
Zn.Trien’+ 
H.Trien+ 
&Trier?+ 
Fe.Trien” 
Pb.Trien’+ 
Mn.Trien’+ 
18.5 86 - 
24.9 9 - 
11.2 3 99 
9.6 2 - 
19.4 -0 100 
21.3 -0 100 
9.8 -0 15 
4.7 -0 0.5 
a Symbols represent anionic forms of the agents defined in the text. In addition, OxPen = oxidized Pen, His = histidinate and 
Cit = citrate. 
b Formation constants have been selected from the literature [ 17,181 and corrected to conform with the temperature and ionic 
strength of blood plasma as previously described [ 21. 
c The percentages refer to a total ligand concentration = 1Om3 mol.dm-’ In general, lower total ligand concentrations will cause 
the figure for the percentage of total metal to decrease, finally becoming zero, whereas there wilI be little change reflected in 
the percentage distribution of the ligand itself. 
d This formation constant is somewhat uncertain. The value used in the computer simulations is probably too low in which case, 
a correspondingly low set of PMI-values are shown in the figure. 
The value of computer models in this field of 
research is well illustrated by the poor &r-excretion 
caused by EDTA in spite of a high equilibrium 
constant [4]. The response is predictable, however, 
in view of the low PM1 computed for this ligand. In 
contrast, any consideration based on the effective 
stability constant calculated by Schubert would lead 
to an erroneous conclusion [ 1 ] . 
The other important aspect of chelation therapy 
which the computer simulations have illuminated 
concerns the distribution of metal-ions amongst 
different body compartments. In general, those 
chelating agents which form charged species are 
confined to the plasma until eliminated by the 
kidneys. Neutral complexes on the other hand 
passively diffuse through membranes so that the 
metal tends to spread throughout the body tissue 
[I41 * 
The models are thus able to explain the medical 
observation that plumbism is best treated in two 
stages - initial EDTA intravenous-infusions are 
followed by longer term oral-therapy with Pen [ 151. 
The negatively charged Pb-EDTA2- complex is 
strongly formed in plasma and quickly removed. 
However, lead which has dispersed into the tissues 
is inefticiently leached back into plasma by the poly- 
aminocarboxylic acid. Pen forms a neutral complex 
which is easily returned to plasma once a favourable 
concentration gradient is established. This also explains 
the experimental finding that early treatment with 
Pen can be detrimental because it actually increases 
lead deposition in essential organs [ 161. Moreover, 
the serious side-effects caused by Zn-deficiency some- 
times associated with Pen-therapy arise because the 
Zn-Pen:- complex predominates. This species is 
negatively charged and hence eliminated into the 
urine [ll]. 
4. Conclusions 
Computationalised approaches can clearly facilitate 
the search for chelating therapeutical replacements. 
Indeed, the design of drugs which can selectively 
137 
alter the concentration of a metal-ion in a specific 
body compartment can now be envisaged. Further, 
the systematic evaluation of proposed new drugs by 
computer simulation would indicate whether physio- 
logical screens hould focus upon trace-metal concen- 
trations more than is customary. In this manner, a 
substantial improvement in drug safety procedures 
could be easily and cheaply accomplished. 
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